title: Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent.
abstract: Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.
authors.affiliation: Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium ; The George Pantziarka TP53 Trust, London KT1 2JP, UK.
authors.forename: Pan
authors.initials: P
authors.lastname: Pantziarka
authors.affiliation: Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
authors.forename: Gauthier
authors.initials: G
authors.lastname: Bouche
authors.affiliation: Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
authors.forename: Lydie
authors.initials: L
authors.lastname: Meheus
authors.affiliation: GlobalCures, Inc; Newton MA 02459, USA.
authors.forename: Vidula
authors.initials: V
authors.lastname: Sukhatme
authors.affiliation: GlobalCures, Inc; Newton MA 02459, USA ; Beth Israel Deaconess Medical Centre and Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Vikas P
authors.initials: VP
authors.lastname: Sukhatme
keywords: ReDO project; cimetidine; drug repurposing; immunostimulant